UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to Sec. 240.14a-12 Grace Therapeutics, Inc.	Filed	illed by the Registrant 🗵			
 □ Preliminary Proxy Statement □ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) □ Definitive Proxy Statement ☑ Definitive Additional Materials □ Soliciting Material Pursuant to Sec. 240.14a-12 Grace Therapeutics, Inc.	Filed	Filed by a Party other than the Registrant □			
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) □ Definitive Proxy Statement □ Definitive Additional Materials □ Soliciting Material Pursuant to Sec. 240.14a-12 Grace Therapeutics, Inc.	Chec	Check the appropriate box:			
 □ Definitive Proxy Statement ☑ Definitive Additional Materials □ Soliciting Material Pursuant to Sec. 240.14a-12 Grace Therapeutics, Inc. 		Preliminary Proxy Statement			
Definitive Additional Materials Soliciting Material Pursuant to Sec. 240.14a-12 Grace Therapeutics, Inc.		Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))			
□ Soliciting Material Pursuant to Sec. 240.14a-12 Grace Therapeutics, Inc.		Definitive Proxy Statement			
Grace Therapeutics, Inc.	\boxtimes	Definitive Additional Materials			
		Soliciting Material Pursuant to Sec. 240.14a-12			
		Grace Therapeutics, Inc.			
(Name of Registrant as Specified In Its Charter)					
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)					
Payment of Filing Fee (Check all boxes that apply):	Payn	ment of Filing Fee (Check all boxes that apply):			
⊠ No fee required	\boxtimes	No fee required			
☐ Fee paid previously with preliminary materials		Fee paid previously with preliminary materials			
☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11		Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11			



GRACE THERAPEUTICS, INC.

2025 Annual Meeting Vote by September 11, 2025 11:59 PM ET



GRACE THERAPEUTICS, INC. 103 CARNEGIE CENTER, SUITE 30 PRINCETON, NEW JERSEY 08540

V76685-P35990

You invested in GRACE THERAPEUTICS, INC. and it's time to vote!

You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on September 12, 2025.

Get informed before you vote

View the Notice and Proxy Statement and Annual Report on Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to August 29, 2025. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.



For complete information and to vote, visit www.ProxyVote.com

Control #

Smartphone users

Point your camera here and vote without entering a control number





Vote Virtually at the Meeting*

September 12, 2025 8:30 a.m. Eastern Time

Virtually at: www.virtualshareholdermeeting.com/GRCE2025

^{*}Please check the meeting materials for any special requirements for meeting attendance.

THIS IS NOT A VOTABLE BALLOT

This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. We encourage you to access and review all of the important information contained in the proxy materials before voting.

Voting Items		Board Recommends		
1.	To elect the five nominees for director named in the Proxy Statement for a one-year term expiring at the 2026 Annual Meeting of Stockholders of Grace Therapeutics, Inc. (the "Company").			
	Nominees:			
	01) Brian Davis 02) Vimal Kavuru 03) Prashant Kohli 04) George Kottayil 05) Edward Neugeboren	⊘ FOR ALL		
2.	To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement.	⊘ FOR		
3.	To ratify the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending March 31, 2026.	⊘ FOR		
NC	NOTE: Such other business as may properly come before the meeting or any adjournment or postponement thereof.			
	Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click "Delivery Setting"	oge"		
	There to receive an email instead: Writie voting on www.roxyvote.com, be sure to click. Delivery setting	195.		